What it is
Livagen (KEDA; Lys-Glu-Asp-Ala) is a short peptide bioregulator associated with liver cell health, gene-expression regulation, chromatin reactivation, and aging-related cellular support.
Mechanism of action
Livagen is studied as a tissue-specific peptide bioregulator. Source literature describes effects on chromatin reactivation, gene expression, and physiologic function in aging and pathology models.
Evidence summary
Evidence is drawn from peptide-bioregulator and aging literature, including liver-polypeptide complex and KEDA studies. Human-grade dosing evidence is limited and should be interpreted conservatively.
Typical dosing protocols
- 20 mg vial reconstituted with 2.0 ml bacteriostatic water
- 1-2 mg subcutaneous daily
- 10-20 day courses, repeated 1-3 times yearly as needed
Side effects & safety
- Injection-site redness, tenderness, itching, or mild swelling
- Headache, fatigue, mild nausea, or digestive changes
- Use caution with complex liver disease or prescription medication regimens
Cited studies
- Lezhava T, et al. (2006). Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Medical News.PMID 16705247Read source โ
- (2020). Influence of liver polypeptide complex and KEDA tetrapeptide on physiological function in aging and pathology. PubMed.PMID 32362099Read source โ
- Kost NV, et al. (2003). Effect of Livagen and Epitalon on enkephalin-degrading enzymes in human serum. PubMed.PMID 12942748Read source โ
- Khavinson V, et al. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules.Read source โ
All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.